Critical Reviews in Oncology / Hematology
Volume 75, Issue 2 , Pages 152-159 , August 2010

Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer

  • Supriya Gupta Mohile

      Affiliations

    • James Wilmot Cancer Center, University of Rochester, Rochester, NY, United States
    • Corresponding Author InformationCorresponding author at: James P. Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, United States. Tel.: +1 585 275 9319; fax: +1 585 273 1042.
    • ,
  • Maureen Lacy

      Affiliations

    • Department of Psychiatry, University of Chicago, Chicago, IL, United States
    • ,
  • Miriam Rodin

      Affiliations

    • Department of Medicine, Section of Geriatrics, St. Louis University, United States
    • ,
  • Kathryn Bylow

      Affiliations

    • Department of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin, United States
    • ,
  • William Dale

      Affiliations

    • Department of Medicine, Division of Geriatrics and Palliative Care, University of Chicago, Chicago, IL, United States
    • ,
  • Michael R. Meager

      Affiliations

    • Department of Psychiatry, University of Chicago, Chicago, IL, United States
    • ,
  • Walter M. Stadler

      Affiliations

    • Department of Medicine, Division of Hematology/Oncology, University of Chicago, Chicago, IL, United States

Received 2 January 2009 ,Revised 18 March 2009 ,Accepted 1 April 2009.

References 

  1. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol. 1996;26:428–438
  2. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295–300
  3. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–479
  4. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998;159(6):2030–2034
  5. Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging. 1999;15(2):131–142
  6. Basaria S, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002;56(6):779–786
  7. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–1106
  8. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1–2):125–132
  9. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148(6):427–434
  10. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin. 2007;25(3):577–609v
  11. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194
  12. Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27(1):22–31
  13. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985–1992
  14. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–394
  15. Lemay S, Bedard MA, Rouleau I, Tremblay PL. Practice effect and test–retest reliability of attentional and executive tests in middle-aged to elderly subjects. Clin Neuropsychol. 2004;18(2):284–302
  16. Meyers J, Meyers K. Rey Complex Figure Test and Recognition Trial. Professional Manual. Palo Alto: Psychological Assessment Resources; 1995;
  17. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125–142
  18. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol. 1999;13(3):348–358
  19. Benedict RH, Schretlen D, Groniger L. Revision of the Brief Visual-Spatial Memory Test: studies of normal performance, reliability, and validity. Psychol Assess. 1996;8:145–153
  20. Vega A. Use of Purdue pegboard and figger tapping performance as a apid screening test for brain damage. J Clin Psychol. 1969;25:255–258
  21. Gallagher D, Nies G, Thompson LW. Reliability of the Beck Depression Inventory with older adults. J Consult Clin Psychol. 1982;50(1):152–153
  22. Gallagher D, Breckenridge J, Steinmetz J, Thompson L. The Beck Depression Inventory and Research Diagnostic Criteria: congruence in an older population. J Consult Clin Psychol. 1983;51(6):945–946
  23. Kendall PC, Finch AJ, Auerbach SM, Hooke JF, Mikulka PJ. The State-Trait Anxiety Inventory: a systematic evaluation. J Consult Clin Psychol. 1976;44(3):406–412
  24. Frerichs RJ, Tuokko HA. Reliable change scores and their relation to perceived change in memory: implications for the diagnosis of mild cognitive impairment. Arch Clin Neuropsychol. 2006;21(1):109–115
  25. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–19
  26. Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int. 2005;96(1):48–53
  27. Chertkow H, Massoud F, Nasreddine Z, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ. 2008;178(10):1273–1285
  28. Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64(11):1853–1859
  29. Spaan PE, Raaijmakers JG, Jonker C. Early assessment of dementia: the contribution of different memory components. Neuropsychology. 2005;19(5):629–640
  30. Ivnik RJ, Smith GE, Petersen RC, et al. Diagnostic accuracy of four approaches to interpreting neuropsychological test data. Neuropsychology. 2000;14(2):163–177
  31. Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006;13(4):362–369
  32. Zehnder AE, Blasi S, Berres M, Spiegel R, Monsch AU. Lack of practice effects on neuropsychological tests as early cognitive markers of Alzheimer disease?. Am J Alzheimers Dis Other Demen. 2007;22(5):416–426
  33. Salminen E, Portin R, Korpela J, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer. 2003;89(6):971–976
  34. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004;93(7):975–979
  35. Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109(4):802–810

☆ This article was originally published in the Journal of Geriatric Oncology 2010;1:13–9. This article is republished with kind permission from the Journal of Geriatric Oncology.

PII: S1040-8428(10)00152-6

doi: 10.1016/j.critrevonc.2010.06.009

Critical Reviews in Oncology / Hematology
Volume 75, Issue 2 , Pages 152-159 , August 2010

Article Tools